RxDoctor Payments Data

Tiffany Kelley

Family · Calhoun, GANPI 1063073625

Payments from drug & device makers

$4,074in general payments, 2019–2025

Across 259 payments — averaging $15.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$728
  • AbbVie$619
  • Lilly USA, LLC$454
  • Pfizer$301
  • Exact Sciences$195
  • GSK$182
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$4,074100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,074 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$28,386
Medicare patients
132
Services billed
622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$29,448
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$29,056
EliquisApixaban20$29,002
JardianceEmpagliflozin18$21,199
XareltoRivaroxaban36$18,597
MounjaroTirzepatide15$17,462
Repatha SyringeEvolocumab11$14,764
FarxigaDapagliflozin Propanediol13$10,007
LinzessLinaclotide12$8,285
Soliqua 100-33Insulin Glargine/Lixisenatide13$5,423
Breo ElliptaFluticasone/Vilanterol11$5,349
Incruse ElliptaUmeclidinium Bromide12$4,751
SymbicortBudesonide/Formoterol Fumarate13$3,054
Ezetimibe177$2,738
Atorvastatin Calcium336$2,136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$182$39,15561 claims
Novo NordiskOzempic$728$29,44830 claims
PfizerEliquis$301$29,00220 claims
Boehringer IngelheimJardiance$108$21,19918 claims
Lilly USA, LLCMounjaro, Humulin N$454$18,88227 claims
AstraZenecaFarxiga, Symbicort$157$13,06026 claims
AbbVieLinzess$619$8,28512 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$79$5,42313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Calhoun

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →